Hoyoung Huh

CIK: 0001401267

Transaction Breakdown

Open Market Buys (P)4 (26.7%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)7 (46.7%)

Compensation grants

Other (G, F, J, C, D, …)4 (26.7%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (3)

AKTX

Akari Therapeutics Plc

Director10% Owner

PLRX

PLIANT THERAPEUTICS, INC.

Director

PKBO

Peak Bio, Inc.

Director10% Owner

Discretionary Trading P&L

Holdings

Transaction History (15 total)

AKTX
Akari Therapeutics Plc
Oct 5, 2026
Award(A)
Direct
6.2K shares at avg. $7.90$49K
AKTX
Akari Therapeutics Plc
Aug 18, 2026
Award(A)
Direct
17.2K shares at avg. $7.90$136K
PLRX
PLIANT THERAPEUTICS, INC.
Jun 11, 2026
Award(A)
Stock Option (Right to Buy)
Direct
70K shares-
AKTX
Akari Therapeutics Plc
Dec 16, 2025
Purchase(P)
Warrants to purchase American Depositary Shares ("ADRs")
Direct
618.7K shares-
AKTX
Akari Therapeutics Plc
Dec 16, 2025
Purchase(P)
Pre-Funded Warrants to purchase ADRs
Direct
618.7K shares at avg. $0.40-
AKTX
Akari Therapeutics Plc
Dec 16, 2025
Purchase(P)
Warrants to purchase ADRs
Direct
3.1M shares-
AKTX
Akari Therapeutics Plc
Dec 16, 2025
Purchase(P)
Pre-Funded Warrants to purchase ADRs
Direct
3.1M shares at avg. $0.40-
PLRX
PLIANT THERAPEUTICS, INC.
Jun 5, 2025
Award(A)
Common Stock (Right to Buy)
Direct
30K shares-
AKTX
Akari Therapeutics Plc
Mar 20, 2025
Award(A)
Stock Option (Right to Buy)
Direct
175K shares-
AKTX
Akari Therapeutics Plc
Mar 20, 2025
Award(A)
Stock Option (Right to Buy)
Direct
225K shares-
AKTX
Akari Therapeutics Plc
Mar 6, 2025
Award(A)
Direct
892.9K shares at avg. $1.12$1000K
PKBO
Peak Bio, Inc.
Nov 14, 2024
Disposition(D)
Indirect
372.9K shares-
PKBO
Peak Bio, Inc.
Nov 14, 2024
Disposition(D)
Direct
4.6M shares-
PKBO
Peak Bio, Inc.
Nov 14, 2024
Disposition(D)
Direct
8.4M shares-
PKBO
Peak Bio, Inc.
Nov 14, 2024
Conversion(C)
Direct
4.6M shares-

		Type	Shares	Price		Ownership
Oct 5, 2026	AKTX Akari Therapeutics Plc	Award(A)	6,160	$7.90	$48,658	Direct
Aug 18, 2026	AKTX Akari Therapeutics Plc	Award(A)	17,249	$7.90	$136,250	Direct
Jun 11, 2026	PLRX PLIANT THERAPEUTICS, INC.	Award(A) Stock Option (Right to Buy)	70,000	-	-	Direct
Dec 16, 2025	AKTX Akari Therapeutics Plc	Purchase(P) Warrants to purchase American Depositary Shares ("ADRs")	618,658	-	-	Direct
Dec 16, 2025	AKTX Akari Therapeutics Plc	Purchase(P) Pre-Funded Warrants to purchase ADRs	618,658	$0.40	-	Direct
Dec 16, 2025	AKTX Akari Therapeutics Plc	Purchase(P) Warrants to purchase ADRs	3,093,293	-	-	Direct
Dec 16, 2025	AKTX Akari Therapeutics Plc	Purchase(P) Pre-Funded Warrants to purchase ADRs	3,093,293	$0.40	-	Direct
Jun 5, 2025	PLRX PLIANT THERAPEUTICS, INC.	Award(A) Common Stock (Right to Buy)	30,000	-	-	Direct
Mar 20, 2025	AKTX Akari Therapeutics Plc	Award(A) Stock Option (Right to Buy)	175,000	-	-	Direct
Mar 20, 2025	AKTX Akari Therapeutics Plc	Award(A) Stock Option (Right to Buy)	225,000	-	-	Direct
Mar 6, 2025	AKTX Akari Therapeutics Plc	Award(A)	892,857	$1.12	$1,000,000	Direct
Nov 14, 2024	PKBO Peak Bio, Inc.	Disposition(D)	372,940	-	$0	Indirect
Nov 14, 2024	PKBO Peak Bio, Inc.	Disposition(D)	4,574,661	-	$0	Direct
Nov 14, 2024	PKBO Peak Bio, Inc.	Disposition(D)	8,382,742	-	$0	Direct
Nov 14, 2024	PKBO Peak Bio, Inc.	Conversion(C)	4,574,661	-	$0	Direct

1-15 of 15 transactions

About Huh Hoyoung

Huh Hoyoung (SEC CIK 0001401267) files insider reports with the SEC as Director of Akari Therapeutics Plc (AKTX), Director of PLIANT THERAPEUTICS, INC. (PLRX) and Director of Peak Bio, Inc. (PKBO).

Signal8 holds 8 ownership filings by Huh Hoyoung (1 Form 3, 7 Form 4), filed between Nov 18, 2024 and Oct 16, 2026. Those filings report 15 transactions, from Nov 14, 2024 to Oct 5, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Huh Hoyoung's filings is in TAMPA, FL.

Recent filings by Huh Hoyoung

Oct 5, 2026: Grant or award of AKTX shares (Form 4, code A).
Aug 18, 2026: Grant or award of AKTX shares (Form 4, code A).
Jun 11, 2026: Grant or award of PLRX derivative securities (Form 4, code A).
Dec 16, 2025: Open-market purchases of AKTX derivative securities (4 lines, Form 4, code P).
Jun 5, 2025: Grant or award of PLRX derivative securities (Form 4, code A).

Other insiders filing for Akari Therapeutics Plc (AKTX)

Prudo-Chlebosz Raymond, Director
Patel Sandip I, Director
Bazemore Robert B, Director
Gaslightwala Abizer, CEO
Patel Samir Rashmikant, Director
Vat-Ho Vatnak, Chief Business Officer

How to read Form 4 transaction codes